Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anidulafungin prophylaxis pharmacokinetics in allo-HSCT or AML-MDS intensive chemotherapy patients
2010-018752-27Phase 4Active
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2010
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of anidulafungin in invasive mycoses and mycoses (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Geometric mean ratio of anidulafungin AUC. Started Aug 2010; status: active.
02
Drugs
anidulafungin
03
Conditions
invasive mycosesmycoses
Beyond the preview
Go deeper on 2010-018752-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018752-27.